<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6697">
  <stage>Registered</stage>
  <submitdate>6/09/2017</submitdate>
  <approvaldate>6/09/2017</approvaldate>
  <nctid>NCT03277196</nctid>
  <trial_identification>
    <studytitle>A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation</studytitle>
    <scientifictitle>A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2017-001379-21</secondaryid>
    <secondaryid>VX15-770-126</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ivacaftor

Experimental: Ivacaftor Arm - 

No Intervention: Observational Arm - 


Treatment: drugs: Ivacaftor
Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the morning dose of the Week 104 Visit.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety assessments based on the number of subjects with adverse events (AEs) and serious adverse events (SAEs) - Number of subjects with AEs and SAEs will be reported.</outcome>
      <timepoint>from baseline through safety follow-up (up to 24 weeks after last dose)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Absolute change in sweat chloride</outcome>
      <timepoint>from baseline through Week 104</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Ivacaftor Arm: Subjects From Study 124 (NCT02725567 ) Part B:

          -  Subjects transitioning from Study 124 Part B must have completed the last study visit
             of Study 124 Part B.

          -  As judged by the investigator, parent or legal guardian must be able to understand
             protocol requirements, restrictions, and instructions; and must sign the informed
             consent form (ICF).

        Ivacaftor Arm: Subjects Not From Study 124 Part B:

          -  Confirmed diagnosis of CF, or 2 CF-causing mutations.

          -  One of the following CFTR mutations on at least 1 allele: G551D, G178R, S549N, S549R,
             G551S, G1244E, S1251N, S1255P, or G1349D. Subjects who have an R117H-CFTR mutation
             will be eligible in regions where ivacaftor is approved for use in subjects 2 through
             5 years of age with an R117H-CFTR mutation.

          -  As judged by the investigator, parent or legal guardian must be able to understand
             protocol requirements, restrictions, and instructions; and must sign the ICF.

        Observational Arm:

          -  Received ivacaftor treatment in Study 124 Part B and elected not to enroll or
             ineligible to enroll in the ivacaftor arm of Study 126.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Ivacaftor Arm: Subjects From Study 124 Part B:

          -  History of any illness or condition that, in the opinion of the investigator, might
             confound the results of the study or pose an additional risk in administering
             ivacaftor to the subject.

          -  Subjects receiving commercially available ivacaftor treatment

        Ivacaftor Arm: Subjects Not From Study 124 Part B:

          -  History of any illness or condition that, in the opinion of the investigator, might
             confound the results of the study or pose an additional risk in administering
             ivacaftor to the subject

          -  An acute upper or lower respiratory infection, or pulmonary exacerbation, or changes
             in therapy for pulmonary disease within 4 weeks of Day 1

          -  Abnormal liver function at screening

          -  Hemoglobin &lt;9.5 g/dL at screening

          -  History of solid organ or hematological transplantation

          -  Use of any moderate or strong inducers or inhibitors of CYP3A within 2 weeks of Day 1

        Observational Arm:

          -  Receiving ivacaftor treatment

        Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>16/08/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>75</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>7/06/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Lady Cilento Children's Hospital - South Brisbane</hospital>
    <postcode>4101 - South Brisbane</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Oxford</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vertex Pharmaceuticals Incorporated</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an
      observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in
      subjects with cystic fibrosis (CF) who are &lt;24 months of age at treatment initiation and have
      a CFTR gating mutation</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03277196</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Medical Information</name>
      <address />
      <phone>617-341-6777</phone>
      <fax />
      <email>medicalinfo@vrtx.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>